経皮パッチの世界市場およびパイプラインの分析 (2015年)

他の医薬品市場と同じく、経皮パッチの分野でも研究開発 (R&D) 活動が継続的に行われ、患者のQoL (生活の質) 向上に貢献していますが、まだごく一部の適応症にしか実際に活用されていません。それでもなお、製薬企業は精力的にR&D活動を続け、経皮パッチが適用される疾患も禁煙・疼痛管理・パーキンソン病・アルツハイマー病・ADHDなどと多様化してきており、世界市場の今後の見通しも明るいものとなっています。

当レポートでは、世界各国における経皮パッチ市場の動向、およびパイプライ製品の開発状況について分析し、経皮パッチの特性や作用機序、全体的な市場構造・動向、パイプライン製品の現在の開発状況、製品単位 (計92製品) の詳細な開発状況、上市済み製品 (計45製品) の販売状況、今後の市場の方向性といった情報をお届けいたします。

第1章 経皮パッチの概略

第2章 経皮パッチの種類

• 単層式／多層式の薬剤入り接着剤
• リザーバつき経皮パッチ
• 基質ベースの経皮パッチ
• 蒸気パッチ
• アクティブ／パッシブパッチ

第3章 経皮パッチのドラッグデリバリ (薬物送達) メカニズム

第4章 経皮パッチの利点

第5章 経皮パッチの世界市場の展望

• 現在の市場シナリオ
• 地域別の動向
• 経皮パッチの臨床パイプラインの概況

第6章 経皮パッチの世界市場のダイナミクス

• 市場にプラスに働いている指標
• 商業化に際しての課題

第7章 経皮パッチの世界市場の将来展望

第8章 経皮パッチの臨床パイプライン：企業別・適応症別・相 (フェーズ) 別

• 不明
• 研究段階
• 前臨床段階
• 臨床段階
• 第I相
• 第I/II相
• 第II相
• 第III相
• 認証前
• 認証済み

第9章 上市済みのM経皮パッチ：企業別・適応症別

第10章 治験が延期・中断された経皮パッチのパイプライン製品：企業別・適応症別・相別

• 開発情報が無いもの
• 治験が中断されたもの
• 市場撤退
• 治験延期

第11章 競争環境

• 3M Pharmaceuticals
• Actavis
• Ethical Holdings
• GalaxoSmithKline
• Johnson & Johnson
• Novartis
• Pfizer
• Proctor & Gamble
• ProStrakan
• UCB pharmaceuticals
• Vaxxas pharmaceutical

図表一覧

Technological progress is continuously increasing allowing pharmaceutical companies to develop newer products with higher pharmacological benefits. Transdermal patches are extension of their continuous efforts due to which several patients have been able to improve quality of life. This market segment has yet to be tapped as only few disease indications are being covered under their treatment. Pharmaceutical companies are increasing their investments in research and development segment to introduce novel products in market. Significant progress has been made in past several decades giving rise to presence of myriad of products in global market. They are far better than their predecessors and coming products are expected to be better than existing transdermal patches. As a result, more number of patients are expected to be opting for transdermal patches in their therapeutic regime.

Utilization of transdermal patch varies from region to region due to which their market is diffused in nature. In both industrially developed and under developed countries their consumption is increasing significantly in past few years. US is one of the largest transdermal patch market across the globe followed by Europe. Investment in research and development allows the continuous entry of new products in US market due to which it has largest market shares across the globe. It is pioneer in this field and first patch was introduced in 1979 to treat motion sickness after its wide spread acceptance patches for angina, high blood pressure and hormone replacement therapy were introduced in US market. Over the year newer categories like smoking cessation, pain management, Parkinson's disease, Alzheimer's disease, ADHD and may others disease indications were added resulting in increased market size.

Clinical pipeline for transdermal patches is becoming strong and various novel therapeutics are at different stages of clinical trials which would enter in market in coming years. It is happening because pharmaceutical companies have identified their commercial potential due to which they are investing more toward research and development segment. Orally administrated drugs are not suitable for all patients as they have gastric reflex problem or may have other gastrointestinal diseases due to which bioavailability is limited. On the other, in blood they may interact with other substance causing reduced pharmacological effects. All these problems are not encountered by patients using the transdermal patches.

New principles are being deciphered and increasing emphasis on including more diseases treatment by transdermal patches is imperative for better health. Owing to increasing disease incidences, it has become necessary to take necessary steps to introduce innovative transdermal patches in global market. Oncology and autoimmune diseases are still untouched by them due to which significant opportunities are left untapped. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. On the other hand, nicotine patches and female contraceptive patches are highly developed and forms largest categories of transdermal patch segment. Disease indications will be increased in coming years and advancements in polymer science is expected to increase the innovation rates. With all these developments, the future of transdermal patch market seems to be optimistic.

“Global Transdermal Patch Market & Pipeline Insight 2015” Report Highlights:

• Mechanism of Transdermal Patch Drug Delivery
• Global Transdermal Patch Market Outlook
• Transdermal Patch Clinical Pipeline by Company, Indication & Phase
• Transdermal Patches in Clinical Pipeline: 96
• Marketed Transdermal Patches: 45
• Global Transdermal Patch Market Future Prospects

Table of Contents

1. Introduction to Transdermal Patch

2. Types of Transdermal Patches

• 2.1. Single/ Multiple-Layer Drug-in-Adhesive
• 2.2. Reservoir Transdermal Patches
• 2.3. Matrix Based Transdermal Patches
• 2.4. Vapor Patch
• 2.5. Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

4. Advantages of Transdermal Patch

5. Global Transdermal Patch Market Outlook

• 5.1. Current Market Scenario
• 5.2. Regional Trends
• 5.3. Transdermal Patch Clinical Pipeline Overview

6. Global Transdermal Patch Market Dynamics

• 6.1. Favorable Market Parameters
• 6.2. Commercialization Challenges

7. Global Transdermal Patch Market Future Prospects

8. Global Transdermal Patch Clinical Pipeline by Company, Indication & Phase

• 8.1. Unknown
• 8.2. Research
• 8.3. Preclinical
• 8.4. Clinical
• 8.5. Phase-I
• 8.6. Phase-I/II
• 8.7. Phase-II
• 8.8. Phase-III
• 8.9. Preregistration
• 8.10. Registered

9. Marketed Transdermal Patch by Company & Indication

10. Suspended & Discontinued Transdermal Patch Clinical Pipeline by Company, Indication & Phase

• 10.1. No Development Reported
• 10.2. Discontinued
• 10.3. Market withdrawal
• 10.4. Suspended

11. Competitive Landscape

• 11.1. 3M Pharmaceuticals
• 11.2. Actavis
• 11.3. Ethical Holdings
• 11.4. GalaxoSmithKline
• 11.5. Johnson & Johnson
• 11.6. Novartis
• 11.7. Pfizer
• 11.8. Proctor & Gamble
• 11.9. ProStrakan
• 11.10. UCB pharmaceuticals
• 11.11. Vaxxas pharmaceutical

List of Figures

• Figure 1-1: Steps Involved in Transdermal Permeation
• Figure 1-2: Ideal Properties of Transdermal Patch
• Figure 2-1: Types of Commercially Available Transdermal Patch
• Figure 3-1: Properties of Transdermal Therapeutics
• Figure 3-2: Components of Transdermal Patch
• Figure 3-3: Types of Permeation Enhancers
• Figure 3-4: Schematic Representation of Iontophoresis
• Figure 3-5: Mechanism of Scopolamine Transdermal Patch
• Figure 3-6: Mechanism of Nicotine Transdermal Patch
• Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
• Figure 4-1: Issues with Traditional Drug Delivery Methods
• Figure 4-2: Advantages of Transdermal Patch
• Figure 4-3: Consistent Drug Supply by Transdermal Patch
• Figure 5-1: Transdermal Patch Clinical Pipeline by Phase (%), 2015
• Figure 5-2: Transdermal Patch Clinical Pipeline by Phase (Number), 2015
• Figure 5-3: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (%), 2015
• Figure 5-4: No Development Reported in Transdermal Patch Clinical Pipeline by Phase (Number), 2015
• Figure 5-5: Discontinued Transdermal Patch Clinical Pipeline by Phase (%), 2015
• Figure 5-6: Discontinued Transdermal Patch Clinical Pipeline by Phase (Number), 2015
• Figure 6-1: Drivers for Transdermal Patch
• Figure 6-2: Transdermal Patch Market Commercialization Challenges